Cancer

Items 671-680 of 729

per page
Set Descending Direction
  1. p53 (polyubiquitinated) (human) (rec.) (His)
    SBB-US0012
    SBB-US0012-C02020 µg
    CHF 639.00
    Ubiquitinated-p53 Western Blot: From left to right: Control His6-p53 (50ng), ubiquitinated-p53 (50ng and 100ng) and ubiquitinated-p53 digested with USP7 (50ng).
  2. PARG (human) (rec.) (His) (active) (10µg)
    BBL-2285
    BBL-2285-C01010 µg
    CHF 782.00
    PARG (human) (rec.) (His) (active) (10µg)
  3. PARG (human) (rec.) (His) (active) (1µg)
    BBL-2283
    BBL-2283-C0011 µg
    CHF 441.00
    PARG (human) (rec.) (His) (active) (1µg)
  4. Parkin (E3 Ligase) (human) (rec.) (His)
    SBB-CE0055
    SBB-CE0055-C05050 µg
    CHF 557.00
    Parkin (E3 Ligase) (human) (rec.) (His)
  5. Parkin E3 Ligase TR-FRET Kit
    SBB-KF0036
    SBB-KF0036-KI011 Kit
    CHF 1'250.00
    Parkin E3 Ligase TR-FRET Kit
  6. PD-1 (human) ELISA Kit
    AG-45B-0015
    AG-45B-0015-KI0196 wells
    CHF 610.00
    Figure: Specific quantitation of APRIL in human serum.
Method: Serum from a healthy patient is left untreated or treated with 1µg/ml of the APRIL receptor, TACI (human):Fc (human) (Prod. No. AG-40B-0079). APRIL levels were measured us
  7. PD-L1 (human) ELISA Kit
    AG-45B-0016
    AG-45B-0016-KI0196 wells
    CHF 610.00
    Figure: Specific quantitation of APRIL in human serum.
Method: Serum from a healthy patient is left untreated or treated with 1µg/ml of the APRIL receptor, TACI (human):Fc (human) (Prod. No. AG-40B-0079). APRIL levels were measured us
  8. Periostin (human) (rec.)
    AG-40B-0104
    AG-40B-0104-C01010 µg
    CHF 170.00
    AG-40B-0104-30103 x 10 µg
    CHF 335.00
  9. Periostin (human) ELISA Kit
    AG-45B-0004
    AG-45B-0004-KI0196 wells
    CHF 580.00
    Periostin (human) ELISA Kit
  10. Periostin (human) Matched Pair Detection Set
    AG-46B-0005
    AG-46B-0005-KI011 Set
    CHF 750.00
    Reagents for 5 x 96-well plates

Items 671-680 of 729

per page
Set Descending Direction
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.